Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)
Refined classification criteria for determining whether a product falls under Medical Device Regulations or Human Medicines Regulations, particularly affecting alcohol-only pre-injection swabs and wipes.
Accurate classification ensures compliance with the correct reporting frameworks, thereby enhancing safety monitoring and regulatory adherence.
Organizations must update their adverse event reporting processes to align with the clarified classification of borderline products effective immediately.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Refinement of criteria used to distinguish between products regulated under Medical Device Regulations 2002 and those under Human Medicines Regulations 2012.
Classification determines the applicable safety reporting framework (MDR vs. GVP). Changes or clarifications in classification affect which adverse event reporting rules and workflows apply to specific 'borderline' products.
Organizations must update their adverse event reporting processes to align with the clarified classification of borderline products effective immediately.
The MHRA has refined criteria for distinguishing between medical devices and medicinal products, particularly affecting the classification of borderline products like alcohol-only pre-injection swabs and wipes. This clarification impacts the applicable safety reporting frameworks (MDR vs. GVP) for adverse event reporting.
What changed: Refined classification criteria for determining whether a product falls under Medical Device Regulations or Human Medicines Regulations, particularly affecting alcohol-only pre-injection swabs and wipes.
Why it matters: Accurate classification ensures compliance with the correct reporting frameworks, thereby enhancing safety monitoring and regulatory adherence.
Practical implication: Organizations must update their adverse event reporting processes to align with the clarified classification of borderline products effective immediately.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
